Equities research analysts expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report $44.50 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $43.80 million and the highest estimate coming in at $45.00 million. Vanda Pharmaceuticals posted sales of $38.48 million during the same quarter last year, which suggests a positive year over year growth rate of 15.6%. The business is expected to report its next earnings report on Wednesday, November 1st.

On average, analysts expect that Vanda Pharmaceuticals will report full-year sales of $44.50 million for the current fiscal year, with estimates ranging from $169.40 million to $172.00 million. For the next year, analysts forecast that the firm will report sales of $206.43 million per share, with estimates ranging from $194.00 million to $218.20 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The business had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. During the same quarter last year, the business posted $0.01 earnings per share. The company’s quarterly revenue was up 16.7% on a year-over-year basis.

Several equities research analysts have recently commented on VNDA shares. Zacks Investment Research cut Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 18th. TheStreet raised Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Friday, May 12th. Piper Jaffray Companies reissued an “overweight” rating and issued a $23.00 target price on shares of Vanda Pharmaceuticals in a research note on Tuesday, June 27th. Jefferies Group LLC reissued a “buy” rating and issued a $21.00 target price on shares of Vanda Pharmaceuticals in a research note on Thursday, May 25th. Finally, HC Wainwright started coverage on Vanda Pharmaceuticals in a research note on Friday, May 26th. They issued a “buy” rating and a $18.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Vanda Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $21.33.

Large investors have recently made changes to their positions in the company. Legal & General Group Plc boosted its stake in shares of Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 3,022 shares during the period. Kopp Investment Advisors LLC bought a new stake in shares of Vanda Pharmaceuticals during the second quarter worth approximately $196,000. Virginia Retirement Systems ET AL bought a new stake in shares of Vanda Pharmaceuticals during the first quarter worth approximately $193,000. Capital Fund Management S.A. bought a new stake in shares of Vanda Pharmaceuticals during the first quarter worth approximately $195,000. Finally, AQR Capital Management LLC bought a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth approximately $223,000. 90.84% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals (VNDA) opened at 16.25 on Wednesday. The company’s 50-day moving average price is $16.18 and its 200 day moving average price is $14.76. Vanda Pharmaceuticals has a 52 week low of $11.58 and a 52 week high of $18.00. The company’s market cap is $728.94 million.

TRADEMARK VIOLATION WARNING: “Vanda Pharmaceuticals Inc. (VNDA) Expected to Announce Quarterly Sales of $44.50 Million” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/16/vanda-pharmaceuticals-inc-vnda-expected-to-announce-quarterly-sales-of-44-50-million.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.